Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease
Exscientia, a leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD).
AD is the most common form of dementia worldwide, with an estimated 44 million people living with AD or related form of dementia.1,2 Symptoms of this progressive disease are debilitating, distressing – for both those with the disease and their loved ones – and there is currently no cure.3
This exciting new partnership unites Exscientia's AI-driven molecular design capabilities with the deep therapy area knowledge and technical expertise of the ARUK-ODDI.
The collaboration will focus on a specific neuroinflammatory pathway implicated in the development of AD. Activation of the NLRP3 inflammasome has been shown to have an important role in AD pathogenesis and, while there have been other efforts to develop anti-inflammatory drugs for AD,4 targeting NLRP3 inflammasome inhibition in the brain is an innovative therapeutic approach.
Exscientia’s proven AI-driven technology will be applied to efficiently generate high-value novel clinical assets targeting this pathway. Feeding into this are chemical starting points that modulate NLRP3 inflammasome formation identified over years of research by the ARUK-ODDI. Coupling Exscientia's Centaur Chemist® AI-design systems with the ARUK-ODDI’s biology and screening expertise is expected to speed up delivery of distinct candidate molecules for AD.
Exscientia’s COO David Hallett commented: “Alzheimer’s is a dreadful disease that affects tens of millions worldwide. Despite clinical trials of numerous agents over a wide range of mechanisms, the last new Alzheimer’s medication, was approved nearly two decades ago. Alzheimer’s drug development is costly, complex and extremely challenging with clinical trial failure rate being the highest of any therapeutic area. Our mission is to make novel drugs available to all and we are excited to utilise our AI drug discovery platform and work alongside the expertise of the Alzheimer’s Research UK-Oxford Drug Discovery Institute team to accelerate innovation and develop potential medicines to solve this global epidemic.”
Expanding on this new relationship, Dr John Davis, CSO of the Alzheimer’s Research UK-Oxford Drug Discovery Institute drew attention to the benefits gained from the complementary capabilities of both partners: "We are delighted to be partnering with Exscientia. Their state-of-the-art AI capabilities will enable us to investigate multiple molecules in parallel and accelerate the project towards candidate declaration. Human genetic variation points towards a critical role for the body’s immune system in an individual’s risk of developing Alzheimer’s disease. It is vital that we develop treatments that target neuroinflammatory mechanisms underlying dementia.”
Dr Sara Imarisio, Head of Research at Alzheimer’s Research UK said:
“Scientist’s at our ARUK-Oxford Drug Discovery Institute are ideally placed to capitalise on the latest discoveries and work with partners to help translate this into drugs that could be tested in clinical trials. With nearly one million people in the UK living with dementia, there isn’t a moment to waste.”
Notes to Editors:
About the NLRP3 inflammasome in the pathophysiology of Alzheimer’s disease (AD)
Inflammasomes are part of the innate immune system and are responsible for a wide range of inflammatory responses. In AD, activated NLRP3 inflammasome leads to the release of pro-inflammatory cytokine (IL-1 beta) and ASC (apoptosis-associated speck-like protein containing a caspase-recruitment domain) speck into the intercellular space. The release of ASC specks from microglia promotes amyloid-beta aggregation in AD. The accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together result in neurodegeneration and cognitive decline that characterize AD.
Exscientia is an Artificial Intelligence (AI)-driven pharmatech, committed to discovering medicines in the fastest and most effective manner for patients. As a clinical stage company, Exscientia is the first to progress AI-designed small molecules into a clinical setting, demonstrating the ability of AI to transform the pharmaceutical industry.
Drug design is precision engineering at the molecular scale. To transform the industry, Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently re-apply enhanced knowledge through iterations of design. Because Exscientia’s AI systems learn more rapidly and effectively than human-led efforts, candidate molecules satisfying complex therapeutic requirements are discovered with revolutionary efficiency.
Exscientia puts AI at the centre of its strategy to revolutionise drug discovery, designing therapeutics for areas of high unmet need, that will positively impact patients.
About Centaur Chemist®
Centaur Chemist® is Exscientia’s solution to AI-driven drug design combining the latest AI-tech with the therapeutic experience of seasoned drug hunters. Driven by algorithms that mimic evolutionary design as well as deep learning to analyse complex information and active learning to extract insights from sparce, high-value datasets, Centaur Chemist® has been skilfully engineered to work with widest range of discovery data to ensure application to the widest range of discovery projects.
Centaur Biologist® supports the discovery and prioritisation of drug targets, ensuring that any candidate molecules developed will be aligned with key therapeutic objectives. With deep learning and vector embedding techniques Centaur Biologist® pinpoints trends and insights from big data and captures semantics that predict new unexpected associations.
About the ARUK-Oxford Drug Discovery Institute, University of Oxford
The Alzheimer’s Research UK Oxford Drug Discovery Institute is a drug discovery team, founded with funding from the charity Alzheimer’s Research UK, with the objective of accelerating the translation of basic science generated within universities towards therapeutic utility. The focus of the team is upon discovering treatments for the neurodegenerative diseases underlying dementia. Although Alzheimer’s disease is the most common cause of dementia and the charity bears its name, the remit of the ARUK-ODDI covers all diseases and mechanisms implicated in the different neurodegenerative diseases that contribute to dementia, including Alzheimer’s disease, Parkinson’s disease, vascular dementia and frontotemporal dementia. For more information, visit https://oxford-ddi.alzheimersresearchuk.org/about-the-institute/.
1 World Health Organization. Fact Sheet. Dementia. Available at: https://www.who.int/news-room/fact-sheets/detail/dementia. Last accessed 10 February 2021
2 Alzheimer’s News Today. Available at: https://alzheimersnewstoday.com/alzheimers-disease-statistics/. Last accessed 10 February 2021
3 NHS. Alzheimer’s Disease. Available at: https://www.nhs.uk/conditions/alzheimers-disease/. Last accessed 10 February 2021
4 Immunity’s flipside: Microglia promote Alzheimer’s pathology during inflammation. Available at: https://www.novusbio.com/antibody-news/immunitys-flipside-microglia-promote-alzheimers-pathology-during-inflammation. Last accessed 10 February 2021
Mark Swindells, Chief Commercial Officer
Anitra Sprauten, Edelman
+44 (0)78 9685 9386
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Velodyne Lidar Announces Executive Appointments to Advance Company’s Continued Global Lidar Market Leadership8.3.2021 12:48:00 CET | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced that it has appointed Sinclair Vass as Chief Commercial Officer, succeeding Mike Jellen. Mr. Vass joins Velodyne from Focuslight Technologies, where he served as Corporate Senior Vice President and was responsible for driving profitable growth as the leader of its Laser Optics Business Unit. As Chief Commercial Officer of Velodyne Lidar, Mr. Vass will be responsible for worldwide sales and deepening the Company’s customer relationships. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005136/en/ Sinclair Vass, Chief Commercial Officer, Velodyne Lidar, Inc. (Photo: Velodyne Lidar, Inc.) In conjunction with Mr. Vass’s appointment, Mr. Jellen has been promoted to Chief Strategy Officer, where he will be responsible for advancing Velodyne’s growth through mergers and acquisitions and corporate development initiatives. Both Mr. Vass and Mr. Jellen will report directly
CLERHP Estructuras Signs a 10,000,000 Euros Equity Commitment With LDA CAPITAL8.3.2021 11:22:00 CET | Press release
CLERHP Estructuras, an Engineering and Construction company based in Murcia (Spain) and listed on the BME GROWTH, has signed a 10 million euros equity commitment with the global alternative investment firm LDA Capital. The Company, with subsidiary companies in Bolivia, Paraguay, and Uruguay, is developing a new software for the AECO sector. CLERHP provides solutions for the optimization of building structures and new applications in the Virtual and Augmented Reality (AR) space for on-site productivity solutions. Juan Andrés Romero, president and CEO of the group stated: “The support of LDA Capital with the 10 million euros equity commitment guarantees our strong growth and will accelerate our digital projects”. Warren Baker, Managing Partner of LDA Capital, commented, “The time has come for the architecture, engineering, construction and owner (AECO) industry to adopt new technologies. As the industry looks to leverage new technology infrastructure to vastly improve the efficiency of p
Laura Schwarz Moves Up at Airship8.3.2021 10:00:00 CET | Press release
The customer engagement platform for major brands Airship, wants to further expand its market leadership in the EMEA region and continue to grow both in market share and awareness. In order to consistently pursue this goal, the company is placing sales responsibility in this region in the hands of Laura Schwarz, who previously demonstrated her expertise as Airship’s Country Manager for Central and Eastern Europe, where she was responsible for new business in this region, among other things. The Munich based sales leader, will be heading the entire sales team across Europe, with the goal to support more European app owners in optimising their mobile marketing strategies. Schwarz, who speaks several languages, looks back on a varied career with different stations. After studying International Management in Heidelberg, she first founded her own company at the age of 22. She worked for the agencies Havas and pilot before discovering SaaS tech sales for herself and developing the DACH marke
Sabio Group Acquires makepositive, Expanding Focus on Customer Relationship Management8.3.2021 10:00:00 CET | Press release
Sabio Group, a leading European full service CX provider, has acquired makepositive, a large UK-based independent Salesforce consulting partner. makepositive will strengthen Sabio’s ability to support customers with transformative cutting-edge CX technologies, particularly addressing the Human Service aspect of the CRM Customer Engagement Centre. Founded in 2003, makepositive is a multi-award-winning Salesforce consulting partner, with circa 180 employees, offices in London and Manchester, and a development centre in India. makepositive has over 120 Salesforce-accredited consultants with 700+ Salesforce certifications amongst them, as well as its own dedicated managed services capability. The company has delivered Salesforce projects for leading organisations, including Allocate, Aston Martin, Fujifilm, Gamma, McCarthy & Stone, Sohonet, Visioncall and Wolseley. “With AI and conversational technologies now handling many routine CX enquiries, contact centre advisors handle a greater prop
Cell Therapy for Cartilage Regeneration Gets a Boost With Hyaluronic Acid Enriched Chondrocytes in a 3D Tissue Engineering Platform8.3.2021 09:20:00 CET | Press release
Regenerative therapy to treat knee joint damages gets a boost with a breakthrough technology of growing ideal type of cartilage cells including chondroprogenitors and mesenchymal stem cells enriched with hyaluronic acid (HA), reported by Dr Shojiro Katoh, President, Edogawa Hospital in “The KNEE” journal (https://doi.org/10.1016/j.knee.2021.02.019). Edogawa Evolutionary Laboratory of Science (EELS) researchers accomplished this feat using a 3D tissue engineering scaffold, without externally added HA or growth factors. They hope this technology will improvise the clinical outcome of Autologous Chondrocyte Implantation (ACI) and Matrix Assisted Chondrocyte Implantation (MACI) treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005305/en/ Edogawa Hospital team that accomplished a novel feat of regenerating osteoarthritis affected knee cartilage tissue through tissue engineering into clinically transplant-worthy cho
Norway Starts Free-Flow Tolling In One Of World´s Deepest Undersea Tunnels - Kapsch TrafficCom reports8.3.2021 09:10:00 CET | Press release
The Norwegian Public Roads Administration (Statens Vegvesen) assigned Kapsch TrafficCom (Kapsch) in October 2020 to deliver a new Multi-Lane Free-Flow (MLFF) tolling system at Ryfast, Norway. Only 13 weeks after the contract signature, the system with 6 tolling points went successfully into operation on February 1, 2021. The Ryfast sub-sea tunnel system runs from the city of Stavanger to the municipality of Strand. It is one of the longest and deepest undersea road tunnels in the world, with the Ryfylke tunnel of 14.3 kilometres length and 292 meters deep. After implementing the high performance system in record time of only 13 weeks, the Kapsch MLFF G3 tolling system is now in operation since the beginning of February. “While we have installed our systems at tunnels, bridges, cities and roadways all around the world, we are proud to be part of the Ryfast project. We are very happy that we have managed to implement a reliable and high-performing system in such a short time", says Mikae
Northern Data closes acquisition of data center site in Northern Sweden and continues successful expansion driven by enormous demand8.3.2021 09:03:00 CET | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87) has successfully closed the acquisition of the site in Northern Sweden near the city of Boden, announced in January, and immediately started to roll out and install the first GPU-based high-performance computing (HPC) hardware. The site is expected to bring the first capacity online within the next weeks and will contribute decisively to the further successful expansion of Northern Data Group's HPC infrastructure and provide direct customer benefits. The highly efficient data center in Northern Sweden is one of up to five new Scandinavian and Canadian sites that the Group is rapidly building and scaling up as part of its expansion and the massive growth in demand for computing power. The sites are operated climate-neutrally using renewable energies and are characterized by scalability, efficiency and cost advantages. Electricity for Northern Data's new site comes from 100 percent renewable energy and is generated by hydropower plants in